

Elevated expression of SLC6A4 encoding the serotonin transporter (SERT) in gilles de la tourette syndrome

Hildonen, Mathis; Levy, Amanda M.; Dahl, Christina; Bjerregaard, Victoria A.; Møller, Lisbeth Birk; Guldborg, Per; Debes, Nanette M.; Tümer, Zeynep

Published in:
Genes

DOI:
[10.3390/genes12010086](https://doi.org/10.3390/genes12010086)

Publication date:
2021

Document Version
Publisher's PDF, also known as Version of record

Citation for published version (APA):
Hildonen, M., Levy, A. M., Dahl, C., Bjerregaard, V. A., Møller, L. B., Guldborg, P., Debes, N. M., & Tümer, Z. (2021). Elevated expression of SLC6A4 encoding the serotonin transporter (SERT) in gilles de la tourette syndrome. *Genes*, 12(1), 1-10. [86]. <https://doi.org/10.3390/genes12010086>

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain.
- You may freely distribute the URL identifying the publication in the public portal.

Take down policy

If you believe that this document breaches copyright please contact rucforsk@ruc.dk providing details, and we will remove access to the work immediately and investigate your claim.

Article

Elevated Expression of *SLC6A4* Encoding the Serotonin Transporter (SERT) in Gilles de la Tourette Syndrome

Mathis Hildonen ^{1,†} , Amanda M. Levy ^{1,†}, Christina Dahl ², Victoria A. Bjerregaard ¹, Lisbeth Birk Møller ^{1,3} , Per Guldborg ^{2,4}, Nanette M. Debes ⁵ and Zeynep Tümer ^{1,6,*} 

- ¹ Kennedy Center, Department of Clinical Genetics, Copenhagen University Hospital, Rigshospitalet, 2600 Glostrup, Denmark; mathis.hildonen@regionh.dk (M.H.); marie.amanda.bust.levy@regionh.dk (A.M.L.); victoria.bjerregaard@regionh.dk (V.A.B.); Lisbeth.Birk.Moeller@regionh.dk (L.B.M.)
- ² Danish Cancer Society Research Center, 2100 Copenhagen, Denmark; chd@cancer.dk (C.D.); perg@cancer.dk (P.G.)
- ³ Institute for Nature, Systems and Models, Roskilde University Center, 4000 Roskilde, Denmark
- ⁴ Department of Cancer and Inflammation Research, Institute for Molecular Medicine, University of Southern Denmark, 5000 Odense, Denmark
- ⁵ Tourette Clinics, Department of Paediatrics, Copenhagen University Hospital, 2730 Herlev, Denmark; nanette.marinette.monique.debes@regionh.dk
- ⁶ Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, 2020 Copenhagen, Denmark
- * Correspondence: zeynep.tumer@regionh.dk
- † Contributed equally.

Abstract: Gilles de la Tourette syndrome (GTS) is a complex neurodevelopmental disorder characterized by motor and vocal tics. Most of the GTS individuals have comorbid diagnoses, of which obsessive-compulsive disorder (OCD) and attention deficit-hyperactivity disorder (ADHD) are the most common. Several neurotransmitter systems have been implicated in disease pathogenesis, and amongst these, the dopaminergic and the serotonergic pathways are the most widely studied. In this study, we aimed to investigate whether the serotonin transporter (SERT) gene (*SLC6A4*) was differentially expressed among GTS individuals compared to healthy controls, and whether DNA variants (the SERT-linked polymorphic region 5-HTTLPR, together with the associated rs25531 and rs25532 variants, and the rare Ile425Val variant) or promoter methylation of *SLC6A4* were associated with gene expression levels or with the presence of OCD as comorbidity. We observed that *SLC6A4* expression is upregulated in GTS individuals compared to controls. Although no specific genotype, allele or haplotype was overrepresented in GTS individuals compared to controls, we observed that the _{LAC}/_{LAC} genotype of the 5-HTTLPR/rs25531/rs25532 three-locus haplotype was associated with higher *SLC6A4* mRNA expression levels in GTS individuals, but not in the control group.

Keywords: SERT; *SLC6A4*; 5-HTT; Gilles de la Tourette syndrome; GTS; OCD; obsessive compulsive disorder; methylation; expression; serotonin



Citation: Hildonen, M.; Levy, A.M.; Dahl, C.; Bjerregaard, V.A.; Birk Møller, L.; Guldborg, P.; Debes, N.M.; Tümer, Z. Elevated Expression of *SLC6A4* Encoding the Serotonin Transporter (SERT) in Gilles de la Tourette Syndrome. *Genes* **2021**, *12*, 86. <https://doi.org/10.3390/genes12010086>

Received: 21 December 2020

Accepted: 9 January 2021

Published: 12 January 2021

Publisher's Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

1. Introduction

Gilles de la Tourette syndrome (GTS) is a childhood-onset neurodevelopmental disorder characterized by at least one vocal and multiple motor tics, which begin before age 18 years and persist at least 1 year. Average age of onset is between 3 and 9 years with a male to female ratio of around 3:1 [1]. Comorbid conditions including obsessive-compulsive disorder (OCD), attention deficit-hyperactivity disorder (ADHD) and autism spectrum disorder (ASD) are present in more than 70% of the GTS individuals [1,2].

GTS is a complex disorder, with a largely unknown aetiology: several environmental factors are thought to interact with multiple genes in yet undiscovered ways. GTS has a high heritability estimate (>0.5) [3,4], but identification of susceptibility genes has been

challenging likely due to the complex and heterogeneous genetic architecture, wherein common and rare variants in various genes and biological pathways are involved [5–8].

Neuroimaging and neurophysiology studies suggest that GTS is associated with altered synaptic neurotransmission systems involving dopamine, serotonin, inhibitory neurotransmitter γ -aminobutyric acid (GABA) and excitatory neurotransmitter glutamate in the cortico-striato-thalamo-cortical circuits [9–11]. Furthermore, candidate gene studies suggest involvement of dopaminergic [12–15], serotonergic [16,17], glutamatergic [18] and histaminergic [19] pathways in GTS pathogenesis. Dopamine neurotransmission is extensively studied in GTS pathology and an alteration of the tonic-phasic dopamine release is considered as a hallmark leading to the designation of the “dopaminergic hypothesis” [20,21]. The connection between serotonin neurotransmission and GTS has, however, been characterized to a lesser extent. As early as 1990, Comings reported decreased serotonin/platelet ratio in a large cohort of GTS individuals and family members [22], and a range of drugs with high affinity for serotonin receptors, mainly atypical antipsychotics, have been used to relieve tics [23]. However, even though the dysfunction of the serotonergic system is thought to be a primary cause in OCD [24], the extent of its involvement in GTS is yet unknown. Serotonin (5-hydroxytryptamine, 5-HT) receptors have been found to both facilitate and inhibit dopamine activity [25–28]. The serotonin transporter (5-HTT, SERT), which regulates serotonergic neurotransmission by retrieving serotonin from the synaptic cleft back to the presynaptic neuron, is capable of dopamine uptake, meaning that it also functions as a dopamine transporter [29]. Furthermore, SERT knockout rats have reduced expression of proteins essential for the glutamatergic synapses [30]. SERT binding potential (BP) has been investigated in GTS [31–34] and reduced SERT BP was observed in both GTS-only and GTS+OCD individuals [32,33] and negatively correlated with tic severity [31]. However, in a recent study, increased SERT BP was observed in GTS+OCD, but not in GTS-only or OCD-only individuals [34], and the differences in methodologies were suggested as an explanation [34]. The serotonin system may thus be involved in GTS pathology directly and/or indirectly through regulation of other neurotransmitter systems, especially the dopaminergic system.

SERT is encoded by *SLC6A4*, which has been implicated in GTS aetiology by several studies: higher blood *SLC6A4* mRNA expression levels were found to correlate with tic severity in GTS [35], elevated *SLC6A4* expression was found in the striatum of rat models of GTS [36] and the rare *SLC6A4* gain-of-function (GOF) variant Ile425Val known to modulate SERT activity was reported to have a higher prevalence in GTS individuals compared to controls [17,37]. The SERT-linked polymorphic region (5-HTTLPR) in the promoter region immediately upstream to *SLC6A4* has been implicated in both OCD [38–40] and GTS aetiology [17]. The 5-HTTLPR polymorphic region is a 43 bp repeat with two common alleles, a long (L) and a short (S) allele. The L allele has been associated with higher *SLC6A4* mRNA expression in blood leading to increased SERT mediated serotonin clearance, and ultimately resulting in reduced serotonergic neurotransmission [41]. *SLC6A4* expression is further modulated by two 5-HTTLPR-adjacent single nucleotide polymorphisms (SNPs) rs25531 (A>G) and rs25532 (C>T). Initially, the 5-HTTLPR/rs25531 L_G allele was found to mimic the 5-HTTLPR S allele regarding expression levels, and only the L_A allele was found to have higher *SLC6A4* expression [39]. Later, when Wendland et al. investigated the variants of the *SLC6A4* promoter region including rs25532, and their effect on mRNA levels, they identified the three-locus haplotype L_{AC} (5-HTTLPR/rs25531/rs25532) as the highest expressing haplotype [38]. At the same time, they reported the L_{AC} haplotype to be overrepresented in OCD individuals compared to controls, and the same haplotype was later found to be more prevalent in GTS individuals compared to controls [17].

Methylation of the *SLC6A4* promoter region has been previously investigated in the peripheral blood of individuals with major depressive disorder [42], children with childhood physical aggression [43] and ADHD [44] and in the saliva of paediatric OCD [45]. In general, increased methylation was observed in affected individuals compared to controls, and hypermethylation of two CpG-sites was also correlated with increased *SLC6A4* mRNA

expression levels in affected individuals [42]. Furthermore, methylation of *SLC6A4* in peripheral blood was correlated with in vivo human brain serotonin synthesis [43]. So far, there are not any studies investigating the methylation of the *SLC6A4* promoter region in GTS individuals, but elevated blood methylation levels of the dopamine D2 receptor gene (*DRD2*) was correlated with tic severity, while DNA methylation of the dopamine transporter (*DAT*) gene (*SLC6A3*) was lower in more severely affected individuals [46].

As associations between *SLC6A4* methylation, expression and gene variants have not been studied in GTS previously, we investigated whether *SLC6A4* was differentially expressed in GTS individuals with or without OCD compared to healthy controls and assessed whether gene variants or promoter methylation of *SLC6A4* were associated with gene expression levels.

2. Materials and Methods

2.1. GTS and Control Cohort

In this study, we included only male individuals to exclude sex-specific methylation differences, as *SLC6A4* promoter region methylation has been shown to be higher in females [47] and GTS is more common in males [1]. The affected individuals are referred to as GTS individuals regardless of the presence of comorbid OCD unless otherwise noted (i.e., GTS-only or GTS+OCD). The GTS cohort comprised 72 male individuals (aged 16.1 ± 4.0) of whom 50 had only GTS (GTS-only), while 22 had GTS and OCD (GTS+OCD). RNA was available from 57 GTS individuals (43 GTS-only and 14 GTS+OCD). GTS individuals were recruited through the Herlev Tourette Clinic (Denmark) and the GTS diagnosis was established by an experienced neuropsychiatrist using DSM-IV-TR criteria (DSM-IV-TR, 2000) and validated clinical instruments were used to assess the presence of comorbidities as described previously [48]. The study was approved by the Danish Institutional Review Board (2011 H-2-2010-144). Control material comprised DNA from 87 anonymized male individuals (aged 17.7 ± 7.1), and RNA was available from 36 of them. The GTS and control cohort are summarized in Supplementary Table S1.

2.2. Genotyping

DNA was extracted from peripheral blood following standard procedures. Genotyping of 5-HTTLPR, rs25531, rs25532 (Supplementary Figure S1), and Ile425Val variants in *SLC6A4* were carried out with PCR followed by Sanger sequencing. PCR was carried out using the HotStarTaq[®] DNA Polymerase kit (Qiagen, Hilden, Germany) with a no-template-control (NTC) included in each run. PCR products were purified using the MultiScreen[®] PCR_μ96 Plate (Millipore, Burlington, MA, USA) according to the manufacturer's instructions and run on a 2% agarose gel (Sigma Aldrich, St. Louis, MO, USA). The long (L allele) and the short (S allele) fragments were excised from the gel and Sanger sequenced using the BigDye[™] Terminator v3.1 Cycle Sequencing kit and analysed on an ABI 3730 DNA analyser (Applied Biosystems, Foster City, CA, USA). Only individuals homozygous for either the S or the L allele were sequenced for rs25531 and rs25532 determination. PCR and Sanger sequencing primers and conditions are listed in Supplementary Tables S2 and S3.

2.3. Expression Analysis

RNA was extracted from peripheral blood following standard procedures. mRNA expression levels of *SLC6A4* were quantified using reverse-transcription quantitative PCR (RT-qPCR). For this, 1 μ g of total RNA was used for cDNA synthesis using the High-Capacity cDNA Reverse Transcription kit (Applied Biosystems) according to manufacturer's instructions, with minor modifications (Supplementary Table S4). qPCR was carried out using TaqMan probes against either *SLC6A4* (#Hs00169010_m1; Applied Biosystems) or *GUSB* (#Hs00939627_m1; Applied Biosystems). All samples were amplified in triplicates on a 7500 Fast Real-Time PCR system (Applied Biosystems). The relative standard curve method was used for calculation and *SLC6A4* mRNA expression levels were normalized to *GUSB* mRNA levels. qPCR conditions are shown in Supplementary Table S5.

2.4. Methylation Analysis

Bisulphite pyrosequencing was used to quantify the degree of DNA methylation at eight CpG-sites within the 799 bp CpG-island at the promoter region of *SLC6A4* (chromosome position chr17: 28562388–28563186, GRCh37/hg19) (Supplementary Figure S2). DNA (200 ng) was bisulphite converted using an EZ DNA Methylation-Gold™ Kit (Zymo Research, Irvine, CA, USA) according to the manufacturer's instructions. PCR was performed using 1 µL of bisulphite-converted DNA with a PyroMark PCR kit (Qiagen) according to the manufacturer's instructions, with minor modifications. Methylation levels were quantified using PyroMark Q48 Autoprep and PyroMark software. Primer sequences and PCR conditions are shown in Supplementary Table S6.

2.5. Statistical Analyses

For statistical analysis of the distribution of 5-HTTLPR (/rs25531/rs25532) genotypes, the Chi-square test was applied. Nonparametric tests (Mann–Whitney U test or Kruskal–Wallis test) were applied to test for difference in continuous variables between two or more categorical variables. The Dunn test with adjustment for multiple comparisons was used as a post hoc pairwise test after significant results in the Kruskal–Wallis test, to determine which categorical variables differed from each other. Linear regression was used to assess whether one continuous variable had an impact on another continuous variable.

To avoid type I errors, Bonferroni correction was applied to the *p*-values where multiple testing was conducted. As eight CpG-sites together with the mean value of all sites were considered in each methylation test, a *p*-value of $0.05/9 = 0.0056$ was taken as threshold for statistical significance. Statistical results of methylation analyses were only reported for the mean of all CpG-sites.

All statistical analyses were performed in either SPSS (IBM, Armonk, NY, USA) or R (<http://www.r-project.org>). Figures were generated using R and RStudio [49], using the packages *ggplot2* and *ggpubr* [50,51].

3. Results

3.1. Genotyping

To investigate whether there was an association between *SLC6A4* promoter variants and GTS, we genotyped all the GTS individuals and the controls, and there was no statistically significant difference neither in the genotype distribution ($n = 159$, $p = 0.243$) nor in the allele frequencies of the 5-HTTLPR polymorphism ($n = 318$, $p = 0.177$) (Table 1).

Table 1. Genotyping summary.

Variable	GTS Individuals	Controls	chi ²	<i>p</i> -Value	OR
Genotype: no. (%)					
Total number of individuals	72	87			
L/L	28 (38.9)	23 (26.4)			
S/L	31 (43.1)	46 (52.9)			
S/S	13 (18.1)	18 (20.7)	2.829	0.243	
Allele: no. (%)					
L	87 (60.4)	92 (52.9)			
S	57 (39.6)	82 (47.1)	1.822	0.177	1.360
Haplotype: no. (%)					
Total number of individuals	41	40			
L _{AC}	47 (57)	42 (52.5)			
L _{AT} , L _G , S	35 (43)	38 (47.5)	0.380	0.538	1.2150

L, long allele; S, short allele; A and G, A- or G-allele in rs25531; T and C, T- or C-allele in rs25532; OR, odds ratio; chi², chi-square.

To determine the distribution of 5-HTTLPR/rs25531/rs25532 haplotypes (L_{AC} compared to all other combinations), we genotyped the two 5-HTTLPR-adjacent SNPs rs25531 (A>G) and rs25532 (C>T) in 41 GTS individuals and 40 controls homozygous for either the S or the L allele. We did not observe any significant difference in the haplotype distribution ($n = 162$, $p = 0.538$) in GTS individuals compared to controls (Table 1). As the rs25532 T allele was not observed in the L_G background, the L_{GC} haplotype will be referred to as L_G , which is in line with the nomenclature from previous publications [17,38]. Finally, we investigated all the GTS individuals and 51 controls for the Ile425Val variant, which was not present in anyone.

3.2. Expression Analysis

We analysed *SLC6A4* mRNA expression levels using RT-qPCR in 57 GTS individuals (43 GTS-only and 14 GTS+OCD) and 36 controls from whom RNA was available and observed a significant difference ($n = 93$, $p < 0.001$) (Figure 1A). A three-way analysis between GTS-only, GTS+OCD and control individuals followed by a pairwise comparison showed significantly higher expression levels in both GTS-only and GTS+OCD individuals compared to controls ($n = 79$, $p_{\text{adj}} < 0.001$) and ($n = 50$, $p_{\text{adj}} < 0.001$), respectively), while there was no significant difference between GTS-only and GTS+OCD individuals ($n = 57$, $p_{\text{adj}} = 0.368$) (Figure 1A).




Figure 1. Expression levels of *SLC6A4* normalized to *GUSB* expression levels in (A) Gilles de la Tourette syndrome (GTS)—only, GTS+obsessive-compulsive disorder (OCD) or GTS—all individuals and controls and (B) GTS—all individuals and controls with different three-locus genotypes (L_{AC}/L_{AC} , L_{AC}/L_G or L_{AT} , or Non- L_{AC}). Box plots indicate median, quartiles and outliers. ***, $p < 0.001$; NS, not significant.

To assess whether *SLC6A4* variants had a modifying effect on gene expression, we examined *SLC6A4* expression levels in GTS individuals and controls with regards to their 5-HTTLPR genotype and three-locus genotype (L_{AC}/L_{AC} , L_{AC}/L_G or L_{AT} , or non- L_{AC}) and did not detect any statistically significant difference (GTS: $n = 57$, $p = 0.555$; controls: $n = 36$, $p = 0.162$) (Supplementary Figure S3). *SLC6A4* expression levels were, however, significantly higher in GTS individuals than in controls when only individuals with the L_{AC}/L_{AC} three-locus genotype were considered ($n = 27$, $p < 0.001$) (Figure 1B). A difference in expression levels between GTS individuals and controls was not observed for the other genotypes (L_{AC}/L_G or L_{AT} : ($n = 9$, $p = 0.167$); Non- L_{AC} : ($n = 16$, $p = 1$)).

3.3. Methylation Analyses

To investigate whether the observed differences in *SLC6A4* expression could be associated with epigenetic regulation, we assessed the DNA methylation levels of eight CpG-sites at the promoter region of *SLC6A4* in all the GTS individuals (50 GTS-only and 22 GTS+OCD) and the controls. One individual (GTS+OCD) was omitted from the analysis, as the DNA sample repeatedly failed the pyrosequencing quality control. The eight CpG sites assessed in this study were selected from a region of the *SLC6A4* CpG island previously investigated in individuals with major depressive disorder [42] and ADHD [44].

There was no significant difference in the mean DNA methylation levels between GTS-only, GTS+OCD and controls ($n = 158$, $p = 0.725$, Supplementary Figure S4), and we did not observe any association between the mean methylation levels and the *SLC6A4* expression ($n = 92$, $p = 0.992$) or the 5-HTTLPR genotype ($n = 158$, $p = 0.253$). Furthermore, methylation levels were not associated with GTS when considering individuals with the L_{AC}/L_{AC} three-locus genotype ($n = 38$, $p = 0.884$) nor any of the other three-locus genotypes (L_{AC}/L_G or L_{AT} : ($n = 11$, $p = 0.850$); Non- L_{AC} : ($n = 31$, $p = 0.842$)).

4. Discussion

To investigate the involvement of the serotonin transporter SERT in GTS pathology, we performed expression analysis, genotyping and methylation analysis of *SLC6A4* in GTS individuals with and without OCD compared to healthy controls. We observed significantly higher *SLC6A4* mRNA levels in GTS individuals compared to controls ($p < 0.001$), with a tendency of higher expression levels of *SLC6A4* mRNA in GTS+OCD individuals compared to GTS-only, although this difference was not statistically significant. Elevated expression levels of *SLC6A4* were previously observed in GTS rat models [36], and taken together these results suggest that increased serotonin clearance due to overexpression of *SLC6A4* may contribute to GTS aetiology. The tendency of higher *SLC6A4* expression levels in GTS+OCD individuals than GTS-only may explain why selective serotonin reuptake inhibitors (SSRIs) are more effective in the treatment of OCD symptoms than the treatment of tics [52]. SSRIs increase the level of serotonin in the synaptic cleft by inhibiting reuptake of serotonin to the presynaptic neuron. If GTS+OCD individuals indeed do have a higher *SLC6A4* expression than those with only GTS, the use of SSRIs would also have a larger counteracting effect on the hyposerotonergic state resulting from the increased *SLC6A4* expression. These results are also in line with the recent study by Müller-Vahl and colleagues, who have shown increased SERT BP in TS+OCD individuals, but not in TS-only individuals, and a significant overall reduction in SERT binding following SSRI treatment [34].

When only considering the individuals with the same genotype, higher expression levels were only observed in GTS individuals with the L_{AC}/L_{AC} genotype compared to the controls. In a previous study, overall higher *SLC6A4* expression levels were detected in human and rat cell lines with the L_{AC}/L_{AC} genotype when using reporter constructs [38], while in our study, the increased expression levels were only observed in GTS individuals, but not in the control individuals. This indicates that an overexpression of *SLC6A4* in the presence of the L_{AC}/L_{AC} genotype is more protruding in GTS individuals with or without OCD, whereas the different three-locus genotypes do not seem to affect *SLC6A4* expression in healthy controls.

In line with some of the other studies [16,53], we did not find any association between GTS diagnosis (with or without OCD) and *SLC6A4* 5-HTTLPR genotype nor allele distribution. Previously, the 5-HTTLPR/rs25331/rs25332 L_{AC} haplotype was associated with OCD [38], and it was shown to be more frequent in GTS individuals compared to controls, in particular in GTS individuals without OCD [17]. In this study, we did not find an association between GTS diagnosis and any of the 5-HTTLPR/rs25331/rs25332 haplotype variants. This is likely to be due to the small size of the present cohort, especially with regards to the number of GTS+OCD individuals ($n = 14$) included in the haplotype analysis. The third locus, rs25532, was included only in a few studies with OCD and/or GTS individuals [17,38,54], but in several other studies, only the distribution of the 5-HTTLPR or

5-HTTLPR/rs25531 variants were investigated [39,53,55,56]. This challenges comparison across studies, which will either be limited by the number of studies, or is potentially erroneous due to different genotyping methodologies. Further studies investigating the distribution and the effect of the three-locus haplotype in larger cohorts of GTS individuals with or without OCD are warranted to provide a clearer picture.

Promoter methylation of *SLC6A4* has not been investigated previously in individuals with GTS. In the present study, we did not observe any differences in the mean DNA methylation levels between GTS individuals with or without OCD and controls. We cannot, however, exclude that inclusion of further sites within the promoter CpG-island may affect the mean methylation levels, as we have investigated only eight selected CpG-sites, which were also employed in other studies [42,44]. In this study, differential methylation was investigated in blood, the only material available from the individuals. It is possible that brain regions, such as caudate nucleus tissue of the basal ganglia, the prefrontal cortex, the thalamus and the putamen known to be involved in GTS pathology, may be differentially methylated [57–61]. Another plausible explanation of the negative findings can be that serotonin expression in GTS individuals is not regulated by DNA methylation.

The *SLC6A4* mRNA upregulation reported in the current study is furthermore in line with the dopamine hypothesis of GTS. Upregulation of SERT would result in increased serotonin clearance, and such a hyposerotonergic state is suggested to cause upregulation post-synaptic 5-HT_{2A} receptors, which may facilitate dopamine release [17,33]. At the same time, SERT is also capable of dopamine uptake [29]. An upregulation of *SLC6A4* expression could thus ultimately lead to abnormal levels of dopamine, a key component in GTS pathology. It is though warranted to investigate larger cohorts, as the size of the present cohort is relatively small.

5. Conclusions

In this study, we show that *SLC6A4* expression is upregulated in GTS individuals, both with and without OCD, compared to controls. Although we did not observe any overrepresentation of any specific genotype in GTS individuals compared to controls, increased expression of *SLC6A4* in GTS individuals may be modulated by the L_{AC}/L_{AC} genotype, as controls with this genotype had normal expression levels. DNA methylation levels at the promoter region of *SLC6A4* were not associated with the presence of GTS (with or without OCD), mRNA expression levels or individual genotypes, suggesting that *SLC6A4* expression is not regulated by DNA methylation of the investigated CpG-sites in the promoter region of the gene.

Supplementary Materials: The following are available online at <https://www.mdpi.com/2073-4425/12/1/86/s1>: Table S1—Patients and controls, Table S2—Genotyping *SLC6A4* (Ile425Val)—Primers and PCR conditions, Table S3—Genotyping *SLC6A4* (5-HTTLPR)—Primers and PCR condition, Table S4—cDNA synthesis, Table S5—Quantitative PCR of *SLC6A4* and *GUSB*—Probes and qPCR conditions, Table S6—Methylation analysis—Primers and PCR conditions, Figure S1—Genomic location of 5-HTTLPR, rs25531 and rs25532, Figure S2—Genomic location of CpG-sites, Figure S3—Expression levels and 5-HTTLPR genotypes, Figure S4—Mean *SLC6A4* methylation levels.

Author Contributions: Conceptualization Z.T.; methodology Z.T.; formal analysis M.H. and A.M.L.; investigation, M.H. and A.M.L.; patient data N.M.D.; data curation M.H. and A.M.L.; writing—original draft preparation M.H. and A.M.L.; writing—review and editing Z.T.; visualization M.H. and A.M.L.; supervision Z.T., P.G., C.D., L.B.M. and V.A.B.; project administration Z.T.; funding acquisition Z.T. and M.H. All authors have read and agreed to the published version of the manuscript.

Funding: This research was funded by Lundbeck Fonden, grant number R100-2011-9332 and Jascha Fonden, grant number 3674.

Institutional Review Board Statement: The study was conducted according to the guidelines of the Declaration of Helsinki, and approved by the Danish Institutional Review Board (2011 H-2-2010-144. Date of approval: 3/3-2016).

Informed Consent Statement: Informed consent was obtained from all subjects involved in the study.

Data Availability Statement: The data presented in this study are available in the Supplementary Materials.

Conflicts of Interest: The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript or in the decision to publish the results.

References

- Hirschtritt, M.E.; Lee, P.C.; Pauls, D.L.; Dion, Y.; Grados, M.A.; Illmann, C.; King, R.A.; Sandor, P.; McMahon, W.M.; Lyon, G.J.; et al. Lifetime prevalence, age of risk, and genetic relationships of comorbid psychiatric disorders in tourette syndrome. *JAMA Psychiatry* **2015**. [\[CrossRef\]](#)
- Burd, L.; Li, Q.; Kerbeshian, J.; Klug, M.G.; Freeman, R.D. Tourette syndrome and comorbid pervasive developmental disorders. *J. Child Neurol.* **2009**. [\[CrossRef\]](#)
- Mataix-Cols, D.; Isomura, K.; Pérez-Vigil, A.; Chang, Z.; Rück, C.; Johan Larsson, K.; Leckman, J.F.; Serlachius, E.; Larsson, H.; Lichtenstein, P. Familial risks of tourette syndrome and chronic tic disorders a population-based cohort study. *JAMA Psychiatry* **2015**. [\[CrossRef\]](#)
- Davis, L.K.; Yu, D.; Keenan, C.L.; Gamazon, E.R.; Konkashbaev, A.I.; Derks, E.M.; Neale, B.M.; Yang, J.; Lee, S.H.; Evans, P.; et al. Partitioning the Heritability of Tourette Syndrome and Obsessive Compulsive Disorder Reveals Differences in Genetic Architecture. *PLoS Genet.* **2013**. [\[CrossRef\]](#)
- Bertelsen, B.; Stefánsson, H.; Riff Jensen, L.; Melchior, L.; Mol Debes, N.; Groth, C.; Skov, L.; Werge, T.; Karagiannidis, I.; Tarnok, Z.; et al. Association of AADAC Deletion and Gilles de la Tourette Syndrome in a Large European Cohort. *Biol. Psychiatry* **2016**. [\[CrossRef\]](#)
- Yu, D.; Sul, J.H.; Tsetsos, F.; Nawaz, M.S.; Huang, A.Y.; Zelaya, I.; Illmann, C.; Osiecki, L.; Darrow, S.M.; Hirschtritt, M.E.; et al. Interrogating the genetic determinants of Tourette's syndrome and other tic disorders through genome-wide association studies. *Am. J. Psychiatry* **2019**. [\[CrossRef\]](#)
- Huang, A.Y.; Yu, D.; Davis, L.K.; Sul, J.H.; Tsetsos, F.; Ramensky, V.; Zelaya, I.; Ramos, E.M.; Osiecki, L.; Chen, J.A.; et al. Rare Copy Number Variants in NRXN1 and CNTN6 Increase Risk for Tourette Syndrome. *Neuron* **2017**. [\[CrossRef\]](#)
- Scharf, J.M.; Yu, D.; Mathews, C.A.; Neale, B.M.; Stewart, S.E.; Fagerness, J.A.; Evans, P.; Gamazon, E.; Edlund, C.K.; Service, S.K.; et al. Genome-wide association study of Tourette's syndrome. *Mol. Psychiatry* **2013**. [\[CrossRef\]](#)
- Draper, A.; Stephenson, M.C.; Jackson, G.M.; Pépés, S.; Morgan, P.S.; Morris, P.G.; Jackson, S.R. Increased GABA contributes to enhanced control over motor excitability in tourette syndrome. *Curr. Biol.* **2014**. [\[CrossRef\]](#)
- Nordstrom, E.J.; Bittner, K.C.; McGrath, M.J.; Parks, C.R.; Burton, F.H. Hyperglutamatergic cortico-striato-thalamo-cortical circuit breaker drugs alleviate tics in a transgenic circuit model of Tourette's syndrome. *Brain Res.* **2015**. [\[CrossRef\]](#)
- Kanaan, A.S.; Gerasch, S.; García-García, I.; Lampe, L.; Pampel, A.; Anwander, A.; Near, J.; Möller, H.E.; Müller-Vahl, K. Pathological glutamatergic neurotransmission in Gilles de la Tourette syndrome. *Brain* **2017**. [\[CrossRef\]](#)
- Herzberg, I.; Valencia-Duarte, A.V.; Kay, V.A.; White, D.J.; Müller, H.; Rivas, I.C.; Mesa, S.C.; Cuartas, M.; García, J.; Bedoya, G.; et al. Association of DRD2 variants and Gilles de la Tourette syndrome in a family-based sample from a South American population isolate. *Psychiatr. Genet.* **2010**. [\[CrossRef\]](#)
- Lee, C.C.; Chou, I.C.; Tsai, C.H.; Wang, T.R.; Li, T.C.; Tsai, F.J. Dopamine receptor D2 gene polymorphisms are associated in Taiwanese children with Tourette syndrome. *Pediatr. Neurol.* **2005**. [\[CrossRef\]](#)
- Liu, S.; Cui, J.; Zhang, X.; Wu, W.; Niu, H.; Ma, X.; Xu, H.; Yi, M. Variable number tandem repeats in dopamine receptor D4 in Tourette's syndrome. *Mov. Disord.* **2014**. [\[CrossRef\]](#)
- Yoon, D.Y.; Rippel, C.A.; Kobets, A.J.; Morris, C.M.; Lee, J.E.; Williams, P.N.; Bridges, D.D.; Vandenberg, D.J.; Shugart, Y.Y.; Singer, H.S. Dopaminergic polymorphisms in Tourette syndrome: Association with the DAT gene (SLC6A3). *Am. J. Med. Genet. Part B Neuropsychiatr. Genet.* **2007**. [\[CrossRef\]](#)
- Dehning, S.; Müller, N.; Matz, J.; Bender, A.; Kerle, I.; Benninghoff, J.; Musil, R.; Spellmann, I.; Bondy, B.; Möller, H.J.; et al. A genetic variant of HTR2C may play a role in the manifestation of Tourette syndrome. *Psychiatr. Genet.* **2010**. [\[CrossRef\]](#)
- Moya, P.R.; Wendland, J.R.; Rubenstein, L.M.; Timpano, K.R.; Heiman, G.A.; Tischfield, J.A.; King, R.A.; Andrews, A.M.; Ramamoorthy, S.; McMahon, F.J.; et al. Common and rare alleles of the serotonin transporter gene, SLC6A4, associated with Tourette's disorder. *Mov. Disord.* **2013**. [\[CrossRef\]](#)
- Crane, J.; Fagerness, J.; Osiecki, L.; Gunnell, B.; Stewart, S.E.; Pauls, D.L.; Scharf, J.M.; Cath, D.; Heutink, P.; Grados, M.; et al. Family-based genetic association study of DLGAP3 in Tourette Syndrome. *Am. J. Med. Genet. Part B Neuropsychiatr. Genet.* **2011**. [\[CrossRef\]](#)
- Karagiannidis, I.; Dehning, S.; Sandor, P.; Tarnok, Z.; Rizzo, R.; Wolanczyk, T.; Madruga-Garrido, M.; Hebebrand, J.; Nöthen, M.M.; Lehmkuhl, G.; et al. Support of the histaminergic hypothesis in tourette syndrome: Association of the histamine decarboxylase gene in a large sample of families. *J. Med. Genet.* **2013**. [\[CrossRef\]](#)

20. Buse, J.; Schoenefeld, K.; Münchau, A.; Roessner, V. Neuromodulation in Tourette syndrome: Dopamine and beyond. *Neurosci. Biobehav. Rev.* **2013**, *37*, 1069–1084.
21. Maia, T.V.; Conceição, V.A. Dopaminergic Disturbances in Tourette Syndrome: An Integrative Account. *Biol. Psychiatry* **2018**, *84*, 332–344.
22. Comings, D.E. Blood serotonin and tryptophan in Tourette syndrome. *Am. J. Med. Genet.* **1990**. [[CrossRef](#)]
23. Budman, C.L. The role of atypical antipsychotics for treatment of Tourette's syndrome: An overview. *Drugs* **2014**, *74*, 1177–1193.
24. Sinopoli, V.M.; Burton, C.L.; Kronenberg, S.; Arnold, P.D. A review of the role of serotonin system genes in obsessive-compulsive disorder. *Neurosci. Biobehav. Rev.* **2017**, *80*, 372–381.
25. Bortolozzi, A.; Díaz-Mataix, L.; Scorza, M.C.; Celada, P.; Artigas, F. The activation of 5-HT_{2A} receptors in prefrontal cortex enhances dopaminergic activity. *J. Neurochem.* **2005**. [[CrossRef](#)]
26. De Deurwaerdère, P.; Navailles, S.; Berg, K.A.; Clarke, W.P.; Spampinato, U. Constitutive Activity of the Serotonin_{2C} Receptor Inhibits In Vivo Dopamine Release in the Rat Striatum and Nucleus Accumbens. *J. Neurosci.* **2004**. [[CrossRef](#)]
27. Esposito, E.; Di Matteo, V.; Di Giovanni, G. Serotonin-dopamine interaction: An overview. *Prog. Brain Res.* **2008**, *172*, 3–6.
28. Sorensen, S.M.; Kehne, J.H.; Fadayel, G.M.; Humphreys, T.M.; Ketteler, H.J.; Sullivan, C.K.; Taylor, V.L.; Schmidt, C.J. Characterization of the 5-HT₂ receptor antagonist MDL 100907 as a putative atypical antipsychotic: Behavioral, electrophysiological and neurochemical studies. *J. Pharmacol. Exp. Ther.* **1993**, *266*, 684–691.
29. Larsen, M.B.; Sonders, M.S.; Mortensen, O.V.; Larson, G.A.; Zahniser, N.R.; Amara, S.G. Dopamine transport by the serotonin transporter: A Mechanistically distinct mode of substrate translocation. *J. Neurosci.* **2011**. [[CrossRef](#)]
30. Brivio, P.; Homberg, J.R.; Riva, M.A.; Calabrese, F. Alterations of Glutamatergic Markers in the Prefrontal Cortex of Serotonin Transporter Knockout Rats: A Developmental Timeline. *Cell. Mol. Neurobiol.* **2019**. [[CrossRef](#)]
31. Heinz, A.; Knable, M.B.; Wolf, S.S.; Jones, D.W.; Gorey, J.G.; Hyde, T.M.; Weinberger, D.R. Tourette's syndrome: [I-123]β-CIT SPECT correlates of vocal tic severity. *Neurology* **1998**. [[CrossRef](#)]
32. Müller-Vahl, K.R.; Meyer, G.J.; Knapp, W.H.; Emrich, H.M.; Gielow, P.; Brücke, T.; Berding, G. Serotonin transporter binding in Tourette Syndrome. *Neurosci. Lett.* **2005**. [[CrossRef](#)]
33. Wong, D.F.; Brašić, J.R.; Singer, H.S.; Schretlen, D.J.; Kuwabara, H.; Zhou, Y.; Nandi, A.; Maris, M.A.; Alexander, M.; Ye, W.; et al. Mechanisms of dopaminergic and serotonergic neurotransmission in Tourette syndrome: Clues from an in vivo neurochemistry study with PET. *Neuropsychopharmacology* **2008**. [[CrossRef](#)]
34. Müller-Vahl, K.R.; Szejko, N.; Wilke, F.; Jakubowski, E.; Geworski, L.; Bengel, F.; Berding, G. Serotonin transporter binding is increased in Tourette syndrome with Obsessive Compulsive Disorder. *Sci. Rep.* **2019**. [[CrossRef](#)]
35. Gunther, J.; Tian, Y.; Stamova, B.; Lit, L.; Corbett, B.; Ander, B.; Zhan, X.; Jickling, G.; Bos-Veneman, N.; Liu, D.; et al. Catecholamine-related gene expression in blood correlates with tic severity in tourette syndrome. *Psychiatry Res.* **2012**. [[CrossRef](#)]
36. Li, J.; Li, Z.; Li, A.; Wang, S.; Qi, F.; Zhao, L.; Lv, H. Abnormal expression of dopamine and serotonin transporters associated with the pathophysiologic mechanism of Tourette syndrome. *Neurol. India* **2010**. [[CrossRef](#)]
37. Kilic, F.; Murphy, D.L.; Rudnick, G. A human serotonin transporter mutation causes constitutive activation of transport activity. *Mol. Pharmacol.* **2003**. [[CrossRef](#)]
38. Wendland, J.R.; Moya, P.R.; Kruse, M.R.; Ren-Patterson, R.F.; Jensen, C.L.; Timpano, K.R.; Murphy, D.L. A novel, putative gain-of-function haplotype at SLC6A4 associates with obsessive-compulsive disorder. *Hum. Mol. Genet.* **2008**, *17*, 717–723. [[CrossRef](#)]
39. Hu, X.Z.; Lipsky, R.H.; Zhu, G.; Akhtar, L.A.; Taubman, J.; Greenberg, B.D.; Xu, K.; Arnold, P.D.; Richter, M.A.; Kennedy, J.L.; et al. Serotonin transporter promoter gain-of-function genotypes are linked to obsessive-compulsive disorder. *Am. J. Hum. Genet.* **2006**. [[CrossRef](#)]
40. Bengel, D.; Greenberg, B.D.; Corá-Locatelli, G.; Altemus, M.; Heils, A.; Li, Q.; Murphy, D.L. Association of the serotonin transporter promoter regulatory region polymorphism and obsessive-compulsive disorder. *Mol. Psychiatry* **1999**. [[CrossRef](#)]
41. Lesch, K.P.; Bengel, D.; Heils, A.; Sabol, S.Z.; Greenberg, B.D.; Petri, S.; Benjamin, J.; Müller, C.R.; Hamer, D.H.; Murphy, D.L. Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. *Science (80-)* **1996**. [[CrossRef](#)]
42. Iga, J.I.; Watanabe, S.Y.; Numata, S.; Umehara, H.; Nishi, A.; Kinoshita, M.; Inoshita, M.; Shimodera, S.; Fujita, H.; Ohmori, T. Association study of polymorphism in the serotonin transporter gene promoter, methylation profiles, and expression in patients with major depressive disorder. *Hum. Psychopharmacol.* **2016**. [[CrossRef](#)]
43. Wang, D.; Szyf, M.; Benkelfat, C.; Provençal, N.; Turecki, G.; Caramaschi, D.; Côté, S.M.; Vitaro, F.; Tremblay, R.E.; Booij, L. Peripheral SLC6A4 DNA methylation is associated with in vivo measures of human brain serotonin synthesis and childhood physical aggression. *PLoS ONE* **2012**. [[CrossRef](#)]
44. Park, S.; Lee, J.M.; Kim, J.W.; Cho, D.Y.; Yun, H.J.; Han, D.H.; Cheong, J.H.; Kim, B.N. Associations between serotonin transporter gene (SLC6A4) methylation and clinical characteristics and cortical thickness in children with ADHD. *Psychol. Med.* **2015**. [[CrossRef](#)]
45. Grünblatt, E.; Marinova, Z.; Roth, A.; Gardini, E.; Ball, J.; Geissler, J.; Wojdacz, T.K.; Romanos, M.; Walitza, S. Combining genetic and epigenetic parameters of the serotonin transporter gene in obsessive-compulsive disorder. *J. Psychiatr. Res.* **2018**. [[CrossRef](#)]
46. Müller-Vahl, K.R.; Loeber, G.; Kotsiari, A.; Müller-Engling, L.; Frieling, H. Gilles de la Tourette syndrome is associated with hypermethylation of the dopamine D2 receptor gene. *J. Psychiatr. Res.* **2017**. [[CrossRef](#)]

47. Palma-Gudiel, H.; Peralta, V.; Deuschle, M.; Navarro, V.; Fañanás, L. Epigenetics-by-sex interaction for somatization conferred by methylation at the promoter region of SLC6A4 gene. *Prog. Neuro-Psychopharmacol. Biol. Psychiatry* **2019**. [[CrossRef](#)]
48. Mol Debes, N.M.M.; Hjalgrim, H.; Skov, L. Validation of the presence of comorbidities in a danish clinical cohort of children with Tourette syndrome. *J. Child Neurol.* **2008**. [[CrossRef](#)]
49. Rstudio, T. *RStudio: Integrated Development for R*; Rstudio Team, PBC: Boston, MA, USA, 2020. Available online: <http://www.rstudio.com> (accessed on 8 January 2021).
50. Wickham, H. *ggplot2: Elegant Graphics for Data Analysis*; Springer: New York, NY, USA, 2016; ISBN 978-3-319-24275-0.
51. Kassambara, A. *ggpubr: 'ggplot2' Based Publication Ready Plots*. R Package Version 0.4.0. 2020. Available online: <https://CRAN.R-project.org/package=ggpubr> (accessed on 8 January 2021).
52. Steeves, T.D.L.; Fox, S.H. Neurobiological basis of serotonin-dopamine antagonists in the treatment of Gilles de la Tourette syndrome. *Prog. Brain Res.* **2008**, *172*, 495–513.
53. Cavallini, M.C.; Di Bella, D.; Catalano, M.; Bellodi, L. An association study between 5-HTTLPR polymorphism, COMT polymorphism, and Tourette's syndrome. *Psychiatry Res.* **2000**. [[CrossRef](#)]
54. Rashidi, F.S.; Ahmadipour, E.; Shiravand, S.; Ahmadiani, A.; Asadi, S.; Shams, J. Association of the functional serotonin transporter haplotype with familial form of obsessive compulsive disorder in Iranian patients. *Int. J. Psychiatry Clin. Pract.* **2018**. [[CrossRef](#)]
55. Voyiaziakis, E.; Evgrafov, O.; Li, D.; Yoon, H.J.; Tabares, P.; Samuels, J.; Wang, Y.; Riddle, M.A.; Grados, M.A.; Bienvenu, O.J.; et al. Association of SLC6A4 variants with obsessive-compulsive disorder in a large multicenter US family study. *Mol. Psychiatry* **2011**. [[CrossRef](#)]
56. Wendland, J.R.; Kruse, M.R.; Cromer, K.C.; Murphy, D.L. A large case-control study of common functional SLC6A4 and BDNF variants in obsessive-compulsive disorder. *Neuropsychopharmacology* **2007**. [[CrossRef](#)]
57. Makki, M.I.; Behen, M.; Bhatt, A.; Wilson, B.; Chugani, H.T. Microstructural abnormalities of striatum and thalamus in children with tourette syndrome. *Mov. Disord.* **2008**. [[CrossRef](#)]
58. Draganski, B.; Martino, D.; Cavanna, A.E.; Hutton, C.; Orth, M.; Robertson, M.M.; Critchley, H.D.; Frackowiak, R.S. Multispectral brain morphometry in Tourette syndrome persisting into adulthood. *Brain* **2010**. [[CrossRef](#)]
59. Müller-Vahl, K.R.; Kaufmann, J.; Grosskreutz, J.; Dengler, R.; Emrich, H.M.; Peschel, T. Prefrontal and anterior cingulate cortex abnormalities in Tourette Syndrome: Evidence from voxel-based morphometry and magnetization transfer imaging. *BMC Neurosci.* **2009**. [[CrossRef](#)]
60. Müller-Vahl, K.R.; Grosskreutz, J.; Prell, T.; Kaufmann, J.; Bodammer, N.; Peschel, T. Tics are caused by alterations in prefrontal areas, thalamus and putamen, while changes in the cingulate gyrus reflect secondary compensatory mechanisms. *BMC Neurosci.* **2014**. [[CrossRef](#)]
61. Segura, B.; Strafella, A.P. Functional imaging of dopaminergic neurotransmission in tourette syndrome. In *International Review of Neurobiology*; Academic Press: Cambridge, MA, USA, 2013.